An independent data monitoring committee has advised Akeso to submit a sNDA to the NMPA for cadonilimab’s approval in gastric ...

KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...